2022-07-28
I present the final draft of my professional valuation of Lockheed Martin Corporation Equity per Share. I spent some hours cleaning up the prose (mostly light editing). I checked the citations, added "C-5" to Lockheed's notable creations, and worked to tighten up the grammar. As always, subsequent readings will inevitably reveal typographical and grammatical errors, but in general, this report is complete.
I welcome any suggestions or complaints. Feedback always helps me improve my writing and my analysis.
(I will be transitioning to work on a write-up on Gilead Sciences starting next week. From time to time I like to brush up on my biochemistry, molecular biology, and Phase Trial Studies.)